Section of Geriatrics, Department of Internal Medicine, School of Medicine, Yale University, New Haven, Connecticut.
Center for Outcomes Research and Evaluation (CORE), Yale-New Haven Health System, New Haven, Connecticut.
J Gerontol A Biol Sci Med Sci. 2019 Nov 13;74(12):1910-1915. doi: 10.1093/gerona/gly283.
To estimate prescribing trends of and correlates independently associated with coprescribing of benzodiazepines and opioids among adults aged 65 years or older in office-based outpatient visits.
I examined a nationally representative sample of office-based physician visits by older adults between 2006 and 2015 (n = 109,149 unweighted) using data from the National Ambulatory Medical Care Surveys (NAMCS). National rates and prescribing trends were estimated. Then, I used multivariable logistic regression analyses to identify demographic and clinical factors associated with coprescriptions of benzodiazepines and opioids.
From 2006 to 2015, 15,954 (14.6%) out of 109,149 visits, representative of 39.3 million visits nationally, listed benzodiazepine, opioid, or both medications prescribed. The rate of prescription benzodiazepines only increased monotonically from 4.8% in 2006-2007 to 6.2% in 2014-2015 (p < .001), and the rate of prescription opioids only increased monotonically from 5.9% in 2006-2007 to 10.0% in 2014-2015 (p < .001). The coprescribing rate of benzodiazepines and opioids increased over time from 1.1% in 2006-2007 to 2.7% in 2014-2015 (p < .001). Correlates independently associated with a higher likelihood of both benzodiazepine and opioid prescriptions included: female sex, a visit for chronic care, receipt of six or more concomitantly prescribed medications, and clinical diagnoses of anxiety and pain (p < .01 for all).
The coprescribing rate of benzodiazepines and opioids increased monotonically over time in outpatient care settings. Because couse of benzodiazepines and opioids is associated with medication burdens and potential harms, future research is needed to address medication safety in these vulnerable populations.
评估 65 岁及以上年龄的成年人在门诊就诊时同时开具苯二氮䓬类药物和阿片类药物的处方趋势,并确定与两者同时开具相关的独立关联因素。
使用国家门诊医疗调查(NAMCS)的数据,我分析了 2006 年至 2015 年间 109149 名老年患者的全国代表性门诊医生就诊样本(未加权)。估计全国的比率和处方趋势。然后,我使用多变量逻辑回归分析来确定与同时开具苯二氮䓬类药物和阿片类药物相关的人口统计学和临床因素。
2006 年至 2015 年,109149 次就诊中有 15954 次(14.6%),代表全国 3930 万次就诊,列出了开具的苯二氮䓬类药物、阿片类药物或两者的处方。单独开苯二氮䓬类药物的处方率从 2006-2007 年的 4.8%单调增加到 2014-2015 年的 6.2%(p<0.001),单独开阿片类药物的处方率从 2006-2007 年的 5.9%单调增加到 2014-2015 年的 10.0%(p<0.001)。苯二氮䓬类药物和阿片类药物的同时开处方率从 2006-2007 年的 1.1%单调增加到 2014-2015 年的 2.7%(p<0.001)。与更高可能性同时开具苯二氮䓬类药物和阿片类药物相关的独立相关因素包括:女性、慢性护理就诊、同时开具六种或更多种药物以及焦虑和疼痛的临床诊断(p<0.01)。
在门诊医疗环境中,苯二氮䓬类药物和阿片类药物的同时开处方率随时间单调增加。由于苯二氮䓬类药物和阿片类药物的使用与药物负担和潜在危害有关,因此需要进一步研究这些脆弱人群的药物安全性。